Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Endo Health Scores A Huge Win

It really is a new Endo Health (NASDAQ:ENDP).

I've gone on at length about how past management did their best to try to ruin a once-strong specialty pharmaceutical business, but the announcement of a deal to acquire Paladin Labs (PLDLF) is a true transformational deal in all of the right ways. Endo still has challenges to deal with, including generic competition for two major products and surgical mesh litigation, but the company seems to be handling the generic issue pretty well and the acquisition of Paladin will significantly expand the company's specialty pharma business and generate substantial tax savings by redomiciling in Ireland.

The only "but" is valuation. While I do believe that Endo Health's guidance on synergies...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details